hVEGF26-104

hVEGF26-104 is a research-stage therapeutic cancer vaccine developed by VU University Medical Center. It consists of a truncated, synthetic three-dimensional (3D)-structured peptide mimic covering amino acids 26–104 of the human VEGF165 isoform (79 amino acids total) with a cysteine-knot fold that mimics the bevacizumab binding site. Formulated with the adjuvant RFASE (Raffinose Fatty Acid Sulphate Ester) in an oil-in-water emulsion, the vaccine is designed to induce a polyclonal antibody response against endogenous vascular endothelial growth factor-A (VEGF-A/VEGF165) to inhibit tumor angiogenesis. Although hVEGF26-104 demonstrated neutralizing antibody induction in nonhuman primates, a Phase I clinical trial (NCT02237638) in patients with advanced solid malignancies showed that the vaccine was safe and well tolerated but failed to induce seroconversion against native hVEGF165 or provide clinical benefit.

Other names

hVEGF26-104/RFASEox-hVEGF26-104ox-hVEGF-26-104ox-hVEGF 26-104